1. A method of treating a neoplasm associated with an overexpression or amplification of HER2 in a mammal in need of said treatment, comprising administering to said mammal an effective amount of any combination of active components comprising: i) an mTOR inhibitor； and ii) HKI-272 containing (E) -N- {4- [3-chloro-4- (2-pyridinylmethoxy) anilino] -3-cyano-7-ethoxy-6-quinolinyl} -4- (dimethylamino) - 2-butenamide, or a derivative, or a pharmaceutically acceptable salt of said compound. 2. The method according to claim 1, characterized in that HKI-272 is (E) -N- {4- [3-chloro-4- (2-pyridinylmethoxy) anilino] -3-cyano-7-ethoxy-6-quinolinyl } -4- (dimethylamino) -2-butenamide or a pharmaceutically acceptable salt of said compound. 3. The method of claim 1, wherein the mTOR inhibitor comprises i) rapamycin or a derivative or analog thereof； or ii) CCI-779 (temsirolimus) or a prodrug, derivative, pharmaceutically acceptable salt or analog of said compound. 4. The method of claim 1, wherein the mTOR inhibitor comprises rapamycin (sirolimus), 42-O- (2-hydroxy) ethylrapamycin, or CCI-779 (temsirolimus). The method according to claim 2, wherein the mTOR inhibitor is CCI-779 (temsirolimus). The method according to claim 5, characterized in that the combination of active components further comprises herceptin (trastuzumab). The method according to claim 5, characterized in that the combination further comprises one or more antitumor alkylating agents, one or more antitumor antimetabolic agents, one or more biochemical immunomodulators, imatinib, one or more EGFR inhibitors, multicinase inhibitors targeted at serine / threonine and tyrosine kinase receptors as �1. Способ лечения новообразования, связанного с избыточной экспрессией или амплификацией HER2 у млекопитающего, нуждающегося в указанном лечении, включающий введение указанному млекопитающему эффективного количества любой комбинации активных компонентов, содержащей:i) ингибитор mTOR； иii) HKI-272, содержащий (Е)-N-{4-[3-х
